When the FDA approves a new cancer treatment, what does it mean for the rest of the world?
Updated: 7 days ago
12 October 2026
When I see a new cancer treatment approved overseas, my first thought is always… could this matter for people like me?
For those of us living with metastatic breast cancer, research is deeply personal. But a US approval and access to treatment in Australia are different milestones.
This week's HER2 positive breast cancer news is a useful example. It gives us something meaningful to follow, while also showing why the words “FDA approved” need a little context.
The recent HER2+ approval
On 7 October 2026, the US Food and Drug Administration approved tucatinib with trastuzumab and pertuzumab as maintenance treatment after induction therapy for adults with unresectable locally advanced or metastatic HER2 positive breast cancer.
The HER2CLIMB-05 trial showed longer progression-free survival. That means more time before cancer progression or death, on average, within the study. Overall survival results were still immature at the FDA's analysis, so this finding should not be described as proof that people live longer or are cured.
Why an FDA decision matters internationally
An approval gives clinicians, researchers and other regulators a public account of the evidence behind a particular treatment use. Its influence can extend well beyond the United States because regulators can collaborate and make use of one another's assessments.
That influence does not create one worldwide approval. Each country retains responsibility for its own regulatory decision, including the approved indication and prescribing information.
For me, that is the distinction worth keeping in mind: progress overseas can be relevant to us, without immediately becoming a treatment option here.
In Australia, the TGA assesses the medicine
The Therapeutic Goods Administration assesses prescription medicines for quality, safety and efficacy before registration on the Australian Register of Therapeutic Goods.
An FDA decision does not automatically authorise the same treatment use in Australia. The exact indication matters: which cancer, which treatment stage, which combination and which patient group.
Recognising a drug name is therefore not enough to establish access to a newly approved use.
Can international approvals help speed things up?
Sometimes. Australia participates in Project Orbis, an FDA initiative that enables collaborative reviews of promising cancer treatments.
The TGA can also use complete assessments from comparable overseas regulators through eligible report-based pathways. These processes can reduce duplication and help regulatory progress move between countries.
They still require an appropriate Australian application. Project Orbis does not automatically qualify a medicine for an expedited pathway, and participating regulators remain independent. Approval dates can differ.
These are possible routes to faster review, not guarantees of approval, funding or a particular access date. The pathways described here do not establish an Australian approval or access date for this specific new tucatinib indication.
The PBS is a separate part of access
TGA registration and Pharmaceutical Benefits Scheme subsidy answer different questions. Registration concerns the medicine's quality, safety and efficacy. The PBS helps make listed medicines more affordable.
The Pharmaceutical Benefits Advisory Committee assesses clinical effectiveness, safety and cost-effectiveness compared with other treatments before recommending a listing. A positive recommendation is required for a new medicine to be listed.
Funding decisions, pricing, supply and the PBS eligibility criteria for the exact treatment use still matter. An existing listing may cover a different combination or treatment stage.
What this means for people living with metastatic cancer
A new option can be an important reason for hope. It also brings very practical questions: does the evidence apply to my circumstances, what are the side effects, and can I access this treatment locally?
Those questions belong in a conversation with our oncology teams. A regulatory announcement alone cannot tell us whether a treatment is right for an individual person.
For me, hope comes from watching evidence grow and options expand. International collaboration can help that progress travel. We can welcome a meaningful step while still being clear about what has, and has not, been established.
Caley x
Research Notes carousel
Sources & further reading
These are primary references used for this article and the accompanying carousel.
Sources checked 12 October 2026. This article is for education and does not replace advice from your oncology team.
You may also like my previous research note: Could metastatic HER2+ become a long-term remission? →
Comments